Zidovudine (Synonyms: Azidothymidine, AZT, NSC 602670, ZDV) |
| Catalog No.GC10637 |
지도부딘은 HIV 감염 치료에 널리 사용되는 뉴클레오사이드 역전사효소 억제제(NRTI)입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 30516-87-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Zidovudine is an inhibitor of the reverse transcriptase of HIV-1[1].
Zidovudine is the first effective agent for the management of HIV-1 infection and is approved by FDA as a drug for AIDs in 1987. As a nucleoside analogue, zidovudine inhibits the activity of the reverse transcriptase with its triphosphate structure. In the in vitro studies, zidovudine shows strong inhibition of HIV-1 replication and the cytopathic effect of the virus. The addition of 5μM and 10μM zidovudine completely protects TM3 cells (a normal IL-2-dependent helper/inducer T-cell clone) and ATH8 cells against the cytopathic effect of HIV. It exhibits complete inhibition of reverse transcriptase at concentration up to 0.5μM. However, the resistance of zidovudine has been found in vitro and in vivo since 1989 [1, 2].
References:
[1] Mitsuya H, Weinhold K J, Furman P A, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences, 1985, 82(20): 7096-7100.
[2] McLeod G X, Hammer S M. Zidovudine: five years later. Annals of internal medicine, 1992, 117(6): 487-501.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *